drugset / Trial / NCT01958970
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a pilot study to assess the safety, pharmacokinetics and effectiveness of PINTA 745 or placebo in treating protein energy wasting (PEW) in patients receiving maintenance hemodialysis (MHD).
Timeline
- Start
- 2014-01
- Primary completion
- 2015-11
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PINTA 745 | Peptide | 1 mg/kg | Intravenous |
| Subject | PINTA 745 | Peptide | 2 mg/kg | Intravenous |
| Subject | PINTA 745 | Peptide | 3 mg/kg | Intravenous |